Quest Diagnostics to Speak at the RBC Capital Markets 2010 Healthcare Conference
Poster: SySAdmin
Posted on March 1, 2010 at 2:56:01 PM
Quest Diagnostics to Speak at the RBC Capital Markets 2010 Healthcare Conference
MADISON, N.J., March 1 -- Quest Diagnostics Incorporated (NYSE:DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the RBC Capital Markets 2010 Healthcare Conference in New York City. The presentation is scheduled for Wednesday, March 3, 2010 at 9:00 a.m. Eastern Time.
During the conference, the company will reaffirm its 2010 guidance for revenue growth of 3% to 4%, operating income to approach 19% of revenues, and diluted earnings per share of between $4.10 and $4.30.
The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.wsw.com/webcast/rbc116/dgx/ and to the public on http://www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available one hour after the conclusion of the live event and will remain available until April 3, 2010.
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at http://www.QuestDiagnostics.com.
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," in "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2009 Annual Report on Form 10-K and other items throughout the Form 10-K and the company's Current Reports on Form 8-K.
Contacts:
Kathleen Valentine (Investors): 973-520-2900
Wendy Bost (Media): 973-520-2800
Source: Quest Diagnostics
CONTACT: Kathleen Valentine (Investors), +1-973-520-2900, or Wendy Bost
(Media), +1-973-520-2800
Web Site: http://www.questdiagnostics.com/
MADISON, N.J., March 1 -- Quest Diagnostics Incorporated (NYSE:DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the RBC Capital Markets 2010 Healthcare Conference in New York City. The presentation is scheduled for Wednesday, March 3, 2010 at 9:00 a.m. Eastern Time.
During the conference, the company will reaffirm its 2010 guidance for revenue growth of 3% to 4%, operating income to approach 19% of revenues, and diluted earnings per share of between $4.10 and $4.30.
The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.wsw.com/webcast/rbc116/dgx/ and to the public on http://www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available one hour after the conclusion of the live event and will remain available until April 3, 2010.
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at http://www.QuestDiagnostics.com.
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," in "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2009 Annual Report on Form 10-K and other items throughout the Form 10-K and the company's Current Reports on Form 8-K.
Contacts:
Kathleen Valentine (Investors): 973-520-2900
Wendy Bost (Media): 973-520-2800
Source: Quest Diagnostics
CONTACT: Kathleen Valentine (Investors), +1-973-520-2900, or Wendy Bost
(Media), +1-973-520-2800
Web Site: http://www.questdiagnostics.com/